Drug Information

Drug General Information
Drug ID
D0O9DK
Former ID
DIB010497
Drug Name
PF-05280586
Indication Cluster headache [ICD10:G44.0] Phase 3 [524870]
Company
Pfizer
Target and Pathway
Target(s) B-lymphocyte antigen CD20 Target Info Antagonist [532698]
KEGG Pathway Hematopoietic cell lineage
References
Ref 524870ClinicalTrials.gov (NCT02213263) A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06). U.S. National Institutes of Health.
Ref 532698Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera?). Toxicol Pathol. 2014 Oct;42(7):1069-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.